Mesyuarat telah bersetuju memberikan kelulusan pendaftaran bersyarat untuk kegunaan semasa bencana bagi dua (2) produk vaksin COVID-19 iaitu:
COVILO Suspension for Injection COVID-19 Vaccine (Vero Cell), Inactivated Pemegang pendaftaran: Duopharma (M) Sdn. Bhd. Pengilang: Beijing Institute of Biological Products Co. Ltd. (BIBP), China COVILO merupakan vaksin yang dibangunkan oleh China National Biotec Group Company Limited (CNBG), Sinopharm, yang juga dikenali sebagai vaksin COVID-19 Sinopharm.
Kenyataan Akhbar KPK 16 Julai 2021 – Keputusan Mesyuarat Pihak Berkuasa Kawalan Dadah Kali Ke-361 Berkenaan Pendaftaran Vaksin COVID-19
Kementerian Kesihatan Kesihatan (KKM) ingin memaklumkan bahawa Mesyuarat Pihak Berkuasa Kawalan Dadah (PBKD) kali ke-361 telah bersidang pada hari ini, 16 Julai 2021. Mesyuarat telah bersetuju memberikan kelulusan pendaftaran bersyarat untuk kegunaan semasa bencana bagi dua (2) produk vaksin COVID-19 iaitu:
1. COVILO Suspension for Injection COVID-19 Vaccine (Vero Cell), Inactivated Pemegang pendaftaran: Duopharma (M) Sdn. Bhd. Pengilang: Beijing Institute of Biological Products Co. Ltd. (BIBP), China COVILO merupakan vaksin yang dibangunkan oleh China National Biotec Group Company Limited (CNBG), Sinopharm, yang juga dikenali sebagai vaksin COVID-19 Sinopharm.
2. Janssen COVID-19 Vaccine Suspension for Injection Pemegang pendaftaran: Johnson & Johnson Sdn. Bhd. Pengilang: Janssen Pharmaceutica N.V., Belgium
Kelulusan pendaftaran bersyarat ini memerlukan maklumat kualiti, keselamatan dan keberkesanan produk vaksin tersebut dipantau dan dinilai berdasarkan data-data terkini dari semasa ke semasa. Ia bagi memastikan perbandingan manfaat-risiko (benefit over risk) bagi produk-produk vaksin tersebut kekal positif.
KKM akan sentiasa mempertingkatkan tahap kesihatan awam dalam memerangi wabak COVID-19 melalui perolehan bekalan vaksin yang telah dinilai daripada aspek kualiti, keselamatan dan keberkesanan oleh Bahagian Regulatori Farmasi Negara (NPRA) dan diluluskan oleh PBKD. Kerajaan juga komited untuk memastikan penduduk dewasa Malaysia mencapai imuniti kelompok (herd immunity) selaras dengan sasaran Program Imunisasi COVID-19 Kebangsaan (PICK).
TAN SRI DATO’ SERI DR. NOOR HISHAM BIN ABDULLAH Ketua Pengarah Kesihatan Malaysia 16 Julai 2021
as I have said many times, only Duopharma and Pharmaniaga are allowed to deal with covid19 vaccines. If you are not pharmaceutical companies, you have no expertise to deal with vaccines and drugs.
Mana promoter ni, buat la kerja, cepat tulis artikel, sinopharm sudah lulus, cakap kata kanger afa buat MoU sama dpharma, nanti kasi up berita. Makan gaji buta la lu olang plomoter, hahaha
Nak execute sale kepala toya ko, lesen dpharma la, ko ingat jual vaksin macam jual kacang putih ke, aduiiiiiii, promote cam budak2 cam ni la nanti price tak bolih jalan, ko ckp.... Kanger to make MoU with dpharma soon, jahahaha, then jual itu MoU nanti ramai lembu2 will buy the kanger stock
@18KHarmoni. I am good. Portfolio getting better. I'm looking for further news about the vaccine distributorship for Kanger. Is it a totally failed plan or not.
By the way, the RI theme is underway. The vaccine plan is a bonus as been said before by a number of us.... INVESTING IS PLAYING A RISKY GAME. He He.
Lol banyak org gila sudah bising sebab kanger tak terbang lagi, tunggu lah khairy akan announce sinopharm dpt beli di swasta, siapa nak cepat boleh pergi swasta ambil sinopharm, kalau tidak tunggu saja perlahan lahan biar covid19 cari kamu, nak tunggukah nak cepat kah, pilihan anda hehe
Duopharma had previously announced a deal to supply the Malaysian government with 6.4 million doses of the Russian-made Sputnik V vaccine. The company did not immediately respond to a request for comment on the health ministry's announcement on Sinopharm.
The predictions only been made by a reference to the news. I'm not insider nor political agent. He He
Report 5: 24 June 2021. “I also anticipate by about August, we will have a private vaccine market. So right now, it’s difficult for private because vaccines are in short supply. But by August, I think that there will be SOME COMPANIES who will be approved to bring in some private vaccines from China. I know SINOPHARM and all that are going to be registered here,” Khairy added.
“That’s also part of the plan. I’ve been talking to the Ministry of Health to ensure that the private market by August can take off to help us.”
...... The immunisation programme now has a total of six vaccines within its portfolio: Sinopharm, Pfizer-BioNTech, AstraZeneca, Sinovac, Cansino, and Johnson & Johnson.
Cuma timbul persoalan. Adakah bekalan untuk swasta dan kerajaan negeri semuanya mesti dibekalkan melalui GLC yang dilantik? Bagaimana dengan permohohan untuk kelulusan sinopharm dari pihak lain selain daripada Duopharma. Adakah ditolak sepenuhnya????
I'm looking for further news about the vaccine distributorship for Kanger. Is it a totally failed plan or not. Just curious about the report given by KJ, on .... SOME COMPANIES
..... I think that there will be SOME COMPANIES who will be approved to bring in some private vaccines from China.
Lalazai9, good point! "Sinopharm will be supplied by Company A" does not mean it cannot be supplied by Company B....it didn't say by A only. What kind of law that allows only one company to sell a legal product? Kanger should continue up trend!
no fact no research, already say is cheap plug... really pls follow the annoucement kanger summit to bursa only write out... if not, u r really 18 ki ho lang kang...
Actually I read this already last month. Hehehe...
Khairy said private companies right now are unable to provide COVID-19 vaccines on the private market due to lack of vaccine supply, however, he added that several private companies will soon be authorised to bring in vaccine supplies directly from China. This would include the Sinopharm COVID-19 vaccine which is expected to be registered soon.
He said he is in talks with the Ministry of Health to ensure that the private vaccine market can take off by August. He added that he has also instructed a GLC pharmaceutical company to start talking to the Chinese suppliers to import vaccines for the private market.
Khairy said “If you want to go fast, you pay-lah” and this would help to accelerate COVID-19 vaccinations in Malaysia.
Post a Comment
People who like this
New Topic
You should check in on some of those fields below.
Title
Category
Comment
Confirmation
Click Confirm to delete this Forum Thread and all the associated comments.
Report Abuse
Please Sign In to report this post as abuse.
Market Buzz
No result.
Featured Posts
MQ Trader
Introducing MY's First IPO Fund for Sophisticated Investors!
MQ Chat
New Update. Discover investment communities that resonate with your ideas
MQ Trader
M & A Value Partners IPO Equity Fund has been launched - Targeted 13% Return p.a
Latest Videos
0:17
New IPO: Mega Fortris Berhad, a manufacturer of security seals, aims to list on the Main Market!
MQ Trader 112 views | 18 h ago
0:17
New IPO: The major provider of road infrastructure construction services in Sabah, Azam Jaya Berhad aims to list on the Main Market!
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
satriahijau
56 posts
Posted by satriahijau > 2021-07-16 11:35 | Report Abuse
18KHarmoni mna awk dpt info ni?